The use of the latter regimen, although more efficient than gemcitabine monotherapy, is probably discouraged in tumours with high TPX2 expression, as it also confers resistance to paclitaxel therapy, at least in vitro [11]. The gene discussed is TPX2; the disease is neoplasm.